Plasma Apolipoproteins A1/B and OxLDL Levels in Patients with Covid-19 As Possible Markers of the Disease

The COVID-19 infection is associated with dyslipidemia and cardiovascular complications. The aim of the study was to determine the content of ApoA1, ApoB, and oxidized low-density lipoproteins (oxLDL) in the plasma of patients ( n = 81) with COVID-19, diabetes, and cardiovascular disease (CVD). ApoA...

Full description

Saved in:
Bibliographic Details
Published inCytology and genetics Vol. 55; no. 6; pp. 519 - 523
Main Authors Pushkarev, V. V., Sokolova, L. K., Chervyakova, S. A., Belchina, Yu. B., Kovzun, O. I., Pushkarev, V. M., Tronko, M. D.
Format Journal Article
LanguageEnglish
Published Moscow Pleiades Publishing 2021
Springer Nature B.V
Subjects
Apolipoproteins
Biomedical and Life Sciences
Biomedicine
Blood levels
Cardiovascular diseases
Coronaviruses
COVID-19
Diabetes
Diabetes mellitus (non-insulin dependent)
Dyslipidemia
Enzyme-linked immunosorbent assay
Human Genetics
Lipoproteins
COVID-19
oxLDL
diabetes mellitus
cardiovascular diseases
apolipoprotein A1
apolipoprotein B
Online AccessGet full text

Cover

More Information
Summary:The COVID-19 infection is associated with dyslipidemia and cardiovascular complications. The aim of the study was to determine the content of ApoA1, ApoB, and oxidized low-density lipoproteins (oxLDL) in the plasma of patients ( n = 81) with COVID-19, diabetes, and cardiovascular disease (CVD). ApoA1, ApoB, and oxLDL were determined using enzyme-linked immunosorbent assay kits (Elabscience, United States). The measurements were performed at an optical wavelength of 450 nm. It was shown that the level of ApoA1 in the blood of patients with type 2 diabetes and especially with COVID-19 was significantly lower than in the blood of healthy people. Blood ApoA1 levels did not show a further decrease in patients with both COVID-19 and diabetes or CVD compared to patients with COVID-19 without concomitant diseases. It was found that the level of ApoB in the blood of patients with diabetes and, especially, with COVID-19 is significantly higher than in the blood of healthy people. Blood levels of ApoB and oxLDL are higher in patients with both COVID-19 and diabetes or CVD compared to patients with COVID-19 without comorbidities. Thus, levels of ApoA1, ApoB, and oxLDL may be promising markers of COVID-19.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0095-4527
1934-9440
DOI:10.3103/S0095452721060116